Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure
Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure is a paper indexed in PICO Portal from OpenAlex.
How many citations does Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure have?
Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure has 54 citations in the OpenAlex counts PICO Portal stores.
When was Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure published?
Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure has 2020 year in the PICO Portal index.
What is the open-access status of Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure?
Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure has hybrid oa status in the PICO Portal index.
What is the DOI of Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure?
The DOI for Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure is on the source record.
What is the PMID of Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure?
The PMID for Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure is on the source record.
What is the OpenAlex record for Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure?
The OpenAlex for Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure is on the source record.